Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes

Short Study Name (acronym):  AIM HIGH 

Long Name: Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes 

Investigators (list PI first):
Jamehl Demons, MD
Jeff Williamson, MD 

Funding Agency:
National Heart, Lung and Blood Institute (NHLBI)
ABBOTT Laboratories 

Funding Dates:
2005-2011 

Research questions or aims:
In patients with established vascular disease and atherogenic dyslipidemia, we plan to compare the efficacy and safety of statin monotherapy (with simvastatin) versus combination therapy (with extended-release niacin plus simvastatin), at comparable levels (<80 mg/dL [2.0 mmol/L]) of on-treatment LDL-C, in reducing the risk for the composite of coronary heart disease (CHD) death, nonfatal myocardial infarction (MI), non-hemorrhagic stroke (fatal or nonfatal), or hospitalization for high-risk non-ST-segment elevation (NSTE) acute coronary syndrome. 

Secondary: 

  • To evaluate the effect of therapy on cardiovascular mortality 
  • To evaluate the effect of therapy on the composite endpoint of CHD death, non-fatal MI, or non-hemorrhagic stroke 

Tertiary: 

  • To evaluate the effect of therapy on  total mortality
  • To evaluate the effect of therapy on the composite endpoint of, or any individual component of the composite endpoint of, CHD death, non-fatal MI, non-hemorrhagic stroke (fatal or nonfatal), hospitalization for NSTE acute coronary syndrome, or any revascularization 
  • To evaluate the effect of therapy for preventing clinical events, as defined above, among patients meeting current criteria for metabolic syndrome as defined by the NCEP ATP III, or future criteria for metabolic syndrome, as they may evolve, or diabetes
         
  • To assess the effects of statin monotherapy versus combination therapy on lipids and lipoproteins, including, but not limited to apoA-I, apoB, apoC-III, Lp(a), HDL subfractions/particle size, LDL size and subclass distribution, and their independent contribution to predicting  outcomes
         
  • To assess the effect of therapy on inflammatory markers such as C-reactive protein and fibrinogen, among others, and their independent contribution to predicting outcomes
         
  • Target population:  High-risk patients with established vascular disease (i.e., those who have a 10-year risk of an event of  ³20%) who have atherogenic dyslipidemia (low HDL-C and high triglycerides).  The vast majority of these patients will qualify for a diagnosis of metabolic syndrome. 

Total enrolled:
Closed enrollment as of March 2010.
Total enrolled across US and Canada :  3400
Number enrolled at this site: 42. 

Dates of enrollment:
2006-2010 

Types of assessments and questionnaires:
Medical History, Demographics, Collection of past Medical Records for verification of established Cardiovascular Disease, QOL questionnaire.  Physical Measurements including: BP readings,   waist and hip measurements, ECG tracings. 

Other data collected:
Fasting lipid panels, AST, Glucose, Creatinine , Uric Acid, Creatinine Kinase.  Carotid MRI, HDL proteomics. 

Study Website (if applicable):  www.AIMHIGH-Heart.com

Coordinator Contact Info:
Patricia Wittmer 
Email:  pwittmer@wakehealth.edu
Phone: 336-414-3441
Fax: 336-379-7776

Quick Reference

Gerontology and Geriatric Medicine

Geriatric Administration
336-713-8570
Geriatric Clinic
336-713-8250
Geriatric Research
336-713-8539
Elder Law Clinic
336-713-8630

Find A Doctor Ways to Give
Last Updated: 03-19-2014
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.